A systematic review of the role of hepatectomy in the management of metastatic renal cell carcinoma - Abstract

AIM: This review sought to systematically appraise the literature to establish the role of hepatectomy in treating renal cell carcinoma hepatic metastases.

METHOD: Medline and EMBASE were systematically searched for papers reporting survival of patients who underwent hepatectomy for metastatic renal cell carcinoma.

RESULTS: Six studies containing 140 patients were included. There were no randomised controlled trials. Perioperative mortality was 4.3%, with reported morbidity between 13 and 30%. Patients with metachronous presentation, and a greater time interval between resection of primary tumour and development of metachronous metastases, appeared to have better survival. There was no difference in survival between patients with solitary and multiple metastases.

CONCLUSION: Few patients with hepatic metastases from renal cell carcinoma are suitable for hepatectomy as metastatic disease is usually widespread. Selected patients may experience a survival benefit, but identifying these patients remains difficult.

Written by:
Grimes NG, Devlin JM, Dunne DF, Jones RP, Poston GJ, Fenwick SW, Malik HZ.   Are you the author?
Royal Victoria Hospital, Belfast BT12 6BA, Northern Ireland, United Kingdom; Altnagelvin Area Hospital, Derry BT47 6SB, Northern Ireland, United Kingdom; Liverpool Hepatobiliary Centre, University Hospital Aintree, Liverpool L9 7AL, United Kingdom.  

Reference: Eur J Surg Oncol. 2014 Aug 27. pii: S0748-7983(14)01054-3.
doi: 10.1016/j.ejso.2014.08.472


PubMed Abstract
PMID: 25228053

UroToday.com Renal Cancer Section